John Sperzel compensation by year
T2 Biosystems Summary Compensation Table · all 2 fiscal years held| Component | FY2022 | FY2023 |
|---|---|---|
| Salary | $575,000 | $575,000 |
| Bonus | $0 | $0 |
| Stock awards | $1,119,840 | $0 |
| Option awards | $0 | $0 |
| Non-equity incentive | $287,500 | $287,500 |
| Pension and deferred compensation | $0 | $0 |
| All other | $3,000 | $3,000 |
| Total | $1,985,340 | $865,500 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: T2 Biosystems, Inc. DEF 14A filed November 20, 2024, accession 0001193125-24-262554, and prior-year filings. Open the filing on EDGAR.
How this page was built: the T2 Biosystems, Inc. filed document, accession 0001193125-24-262554. Every figure is read from that document and cited to the page and table it appears in. Filed November 20, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 587 | $5,750 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in T2 Biosystems, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2023 proxy (filed November 20, 2024)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2024-11-04 | Grant or award derivative | — | 490,000 | $0.00 | 490,000 |
| 2024-11-04 | Grant or award derivative | — | 490,000 | $0.00 | 490,000 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
T2 Biosystems’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| John Sperzel · this page | President, Chief Executive Officer and Chairman of the Board of Directors | $865,500 |
| Michael Gibbs | SVP and General Counsel | $622,600 |
| John Sprague | Chief Financial Officer | $581,000 |
Board service
T2 Biosystems board · FY2023How this board is paid
Company policy: T2 Biosystems pays directors a $40,000 cash retainer and $0 in RSUs. As stated in T2 Biosystems's FY2023 proxy.
The full T2 Biosystems compensation record
free company briefThis page is one person within T2 Biosystems's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are T2 Biosystems's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.